Literature DB >> 11309280

Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation.

F Lohr1, D Y Lo, D A Zaharoff, K Hu, X Zhang, Y Li, Y Zhao, M W Dewhirst, F Yuan, C Y Li.   

Abstract

Plasmids may have unique advantages as a gene delivery system. However, a major obstacle is the low in vivo transduction efficiency. In this study, an electroporation-based gene transduction approach was taken to study the effect of interleukin (IL)-2 or IL-12 gene transduction on the growth of experimental murine tumors. Significant intratumoral gene transduction was achieved by electroporation of tumors that had been injected with naked plasmids encoding reporter genes and cytokine genes (IL-2 and IL-12) under the control of a constitutive cytomegalovirus promoter. In addition, significant tumor growth delay could be achieved in a murine melanoma line B16.F10 with the cytokine genes. Most importantly, systemic transgene levels were negligible when compared with intratumoral adenovirus-mediated IL-12 gene delivery, which leads to significantly higher systemic cytokine levels. Therefore, naked plasmid- and in vivo electroporation-mediated cancer gene therapy may be therapeutically efficacious while maintaining low systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309280

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

2.  Current Progress in Electrotransfection as a Nonviral Method for Gene Delivery.

Authors:  Lisa D Cervia; Fan Yuan
Journal:  Mol Pharm       Date:  2018-06-20       Impact factor: 4.939

3.  Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

Authors:  Samantha K Greaney; Alain P Algazi; Katy K Tsai; Kathryn T Takamura; Lawrence Chen; Christopher G Twitty; Li Zhang; Alan Paciorek; Robert H Pierce; Mai H Le; Adil I Daud; Lawrence Fong
Journal:  Cancer Immunol Res       Date:  2019-12-18       Impact factor: 11.151

4.  APOBEC3A intratumoral DNA electroporation in mice.

Authors:  A Kostrzak; V Caval; M Escande; E Pliquet; J Thalmensi; T Bestetti; M Julithe; L Fiette; T Huet; S Wain-Hobson; P Langlade-Demoyen
Journal:  Gene Ther       Date:  2016-11-18       Impact factor: 5.250

5.  Optimization of a plasma facilitated DNA delivery method.

Authors:  Richard J Connolly; Andrew M Hoff; Richard Gilbert; Mark J Jaroszeski
Journal:  Bioelectrochemistry       Date:  2014-10-13       Impact factor: 5.373

6.  Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation.

Authors:  K E Ugen; M A Kutzler; B Marrero; J Westover; D Coppola; D B Weiner; R Heller
Journal:  Cancer Gene Ther       Date:  2006-06-09       Impact factor: 5.987

Review 7.  Physical non-viral gene delivery methods for tissue engineering.

Authors:  Adam J Mellott; M Laird Forrest; Michael S Detamore
Journal:  Ann Biomed Eng       Date:  2012-10-26       Impact factor: 3.934

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Electric field-mediated transport of plasmid DNA in tumor interstitium in vivo.

Authors:  Joshua W Henshaw; David A Zaharoff; Brian J Mossop; Fan Yuan
Journal:  Bioelectrochemistry       Date:  2007-08-01       Impact factor: 5.373

Review 10.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.